Association of favorable outcome with CBS and FVH score
| Favorable Outcome | Unadjusted | Adjustedb | ||||
|---|---|---|---|---|---|---|
| No | Yes | OR (95% CI) | P | OR (95% CI) | P | |
| Complete case analysis | (n = 151) | (n = 165) | ||||
| CBS (median) (IQR) | 6 (5–8) | 7 (6–8) | 1.12 (1.01–1.23)c | .02 | 1.05 (0.93–1.19)c | .38 |
| ≥6 (No.) (%) | 95 (62.9) | 125 (75.8) | 1.84 (1.13–3.00) | .01 | 1.35 (0.75–2.41) | .31 |
| FVH (median) (IQR) | 2 (1–4) | 3 (1–4) | 1.17 (1.03–1.32)c | .01 | 1.14 (0.98–1.33)c | .07 |
| Sensitivity analysisa | (n = 218) | (n = 198) | ||||
| CBS (median) (IQR) | 6 (4–8) | 7 (5–8) | 1.15 (1.04–1.26)c | .003 | 1.05 (0.94–1.18)c | .37 |
| ≥6 (No.) (%) | 134 (61.6) | 150 (75.6) | 1.93 (1.24–3.00) | .003 | 1.33 (0.78–2.27) | .29 |
| FVH (median) (IQR) | 2 (0–3) | 3 (1–4) | 1.21 (1.08–1.35)c | <.001 | 1.17 (1.02–1.34)c | .02 |
↵a Sensitivity analysis was performed in all patients with MR imaging (n = 416) after handling missing values by multiple imputation.
↵b Prespecified adjustment on study (ASTER versus THRACE), age, sex, admission NIHSS, intravenous tPA, and onset-to-groin puncture time.
↵c OR per 1-point increase in CBS or FVH.